Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
- Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn
BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will host a virtual key opinion leader event on October 19, 2023 at 11:30 am ET to discuss the patient care landscape for hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) and the significant needs that exist for earlier diagnosis and approved treatment options. The potential of Akari’s investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4), as a potential treatment for HSCT-TMA also will be discussed.
The webinar event will feature Sonata Jodele, MD, Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at the University of Cincinnati Department of Pediatrics and Professor Rob Wynn of Royal Manchester Children’s Hospital, part of Manchester University NHS Foundation Trust. The Akari management team will present an overview of nomacopan and an update on the two registrational Phase 3 clinical trials investigating nomacopan as a potential treatment option for pediatric and adult HSCT-TMA.
A live question and answer session will follow the formal presentations. To register for the event, click here. A replay will be available after the event.
About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA and orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation. Akari’s pipeline also includes a clinical program developing nomacopan for adult HSCT-TMA and pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result there; difficulties enrolling patients in our clinical trials; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
For more information
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Orkuveita Reykjavíkur – Green Bond Auction Results4.10.2023 22:52:23 CEST | Press release
Today, October 4th, 2023, Reykjavík Energy (Orkuveita Reykjavíkur; OR) concluded a green bond auction in the green bond classes OR020934 GB and OR180255 GB. OR020934 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of September 2nd, 2034. Previously, bonds have been issued in the category with a nominal value of ISK 18,947 million. The series attracted bids totaling ISK 2,220 million nominal value at yields between 4.16% and 4.30%. OR accepted bids amounting to ISK 2,180 million at a yield of 4,27%. OR180255 GB bears fixed indexed interest and pays equal payments every six months with a final maturity date of February 18th, 2055. Previously, bonds in the category have been issued with a nominal value of ISK 26,201 million. The series attracted bids totaling ISK 1,080 million nominal value at yields between 3.77% and 3.85%. OR accepted bids amounting to ISK 1,080 million at a yield of 3.85%. Fossar Investment Bank oversees the issuance
CNH Industrial: Periodic Report on $300 Million Buyback Program4.10.2023 22:30:00 CEST | Press release
Basildon, October 4, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under the sixth $50 million tranche (the “Sixth Tranche”) of its $300 million share buyback program the Company completed transactions in the period September 18, 2023 to September 22, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the Sixth Tranche, the total invested amount in the Sixth Tranche is approximately €21,868,112.36 ($23,678,032.88) or a total amount of 1,771,134 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (*) excluding fees(€)(€)($) September 25, 2023 87,600 11.3821 997,071.96 1,060,186.62 September 26, 2023 69,635 11.3500 790,357.25 838,173.86 157,235 - 1,787,429.211,898,360.48 (*) All translations determined from Euro to US Dollar at the exchange rate reported by the European Central Bank on t
PHAXIAM Receives Compliance Notice from Nasdaq4.10.2023 22:05:00 CEST | Press release
PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2). With closing bid price of PHAXIAM’s American Depositary Shares (“ADSs”) above $1.00 per ADS for the 10 consecutive business days from September 18 through September 29, 2023, PHAXIAM has regained compliance with Listing Rule 5550(a)(2). On October 7, 2022, PHAXIAM, formerly Erytech Pharma, had received notification from The Nasdaq Stock Market LLC indicating that, based upon a closing bid price of less than $1.00 per ADS for the prior 30 consecutive business day period, the Company no longer satisfied Nasdaq’s rule on minimum bid price. On July 27, 2023, PHAXIAM announced a 10-to-1 reverse share split of its shares and ADSs to cure this deficiency, and the reverse share and ADS splits were effected
SCOR announces the acquisition of 9,000,000 of its own shares upon the partial exercise of the call option granted by Covéa in 2021, and the subsequent sale of these shares to BNP Paribas Cardif4.10.2023 21:58:28 CEST | Press release
Press Release 4 October 2023 - N° 19 SCOR announces the acquisition of 9,000,000 of its own shares upon the partial exercise of the call option granted by Covéa in 2021, and the subsequent sale of these shares to BNP Paribas Cardif Under the June 2021 settlement agreement entered into between SCOR and Covéa in the presence of the Autorité de Contrôle Prudentiel et de Résolution, Covéa granted SCOR a binding and irrevocable call option on its full stake in SCOR – representing 8.8% of the share capital1 – at a price of EUR 28 per share. The board of directors of SCOR authorized today the partial exercise of this call option for the purchase of 9,000,000 SCOR shares held by Covéa, representing 5.01% of SCOR’s share capital1. Once delivered by Covéa to SCOR, the shares will be sold to BNP Paribas Cardif through an over-the-counter transaction. These transactions aim to normalise SCOR’s shareholding. * * * Contact details Media Relations Alexandre Garcia firstname.lastname@example.org Investor Relations Yv
Azerion publishes Notice of Extraordinary General Meeting to be held on 16 November 20234.10.2023 21:50:09 CEST | Press release
Amsterdam, 4 October 2023 – Azerion Group N.V. has today published the Notice of Extraordinary General Meeting 2023 (EGM), which will be held on 16 November 2023. The notice, agenda and accompanying explanatory notes have been published on our website www.azerion.com/egm/ The agenda of the EGM comprises the appointment of two Supervisory Board members. Further information regarding the registration and attendance of the EGM, as well as instructions and deadlines on how to vote and submit questions, can be found on our website http://www.azerion.com/egm/ About Azerion Founded in 2014, Azerion (EURONEXT: AZRN) is one of Europe’s largest digital advertising and entertainment media platforms. We bring global scaled audiences to advertisers in an easy and cost-effective way, delivered through our proprietary technology, in a safe, engaging, and high-quality environment, utilizing our strategic portfolio of owned and operated content with entertainment and other digital publishing partners.